Utilizing the DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay) platform’s unique chemical properties of lanthanide chelates in concert with time-resolved fluorescence (TRF) detection, BioAgilytix is able to develop assays that offer high sensitivity, wide dynamic range, superior stability, and excellent flexibility.
Learn More About the DELFIA Platform:
BioAgilytix’s experts are here to help. Let’s schedule a conversation to review your questions and requirements with one of our scientists.
DELFIA is a heterogeneous, time-resolved fluorescence (TRF) assay method that detects reagents labeled with lanthanide chelates containing Europium (Eu), Terbium (Tb) or Samarium (Sm). Depending on the analyte and antibodies, as well as the required level of sensitivity and dynamic range, these lanthanide-labeled immunoreagents can be applied in non-competitive (sandwich-type) or competitive TRF assays. DELFIA assays are performed on 96- or 384-well formats, using an antibody coated plate to capture target analytes in a sample.
A DELFIA assay is virtually identical to that of a standard sandwich ELISA, with the analyte first captured on the coated microplate, and the detection antibody added to complete the sandwich. But unlike ELISA, a lanthanide chelate-labeled detection antibody is used, and an enhancement step unique to DELFIA releases the lanthanide from the antibody complex, producing a new, highly fluorescent lanthanide chelate contained within a protective micelle.
The highly fluorescent lanthanide chelates yielded possess properties that enable delayed signal measurement at a wavelength that provides for little background interference for superior detection sensitivity via time-resolved fluorometry.
Our passion for the science of small and large molecule bioanalysis drives our ability to deliver premium, tailored services for biomarker, immunogenicity, pharmacokinetics (PK), and cell-based assays.
The DELFIA platform offers excellent flexibility for a range of applications, when the assay must be highly sensitive, specific, reliable, and reproducible. For this reason, it is ideal for complex sample matrices and is particularly well suited for TRF, kinase, and immunodetection assays, as well as discovery work. The wide dynamic range of DELFIA immunoassays also make them ideal for post-screening applications such as PK, ADA, biomarker and cell-based assay support.
BioAgilytix uses the DELFIA platform for complex matrices and for diverse applications including biomarkers, immunogenicity, pharmacokinetics (PK), and cell-based assays, as well as for TRF, kinase, and immunodetection assays.
Biomarkers
Immunogenicity
Pharmacokinetics
Cell-Based Assays
The key benefit of the DELFIA platform is its high sensitivity and ability to accurately detect picogram quantities of analytes. In contrast to standard fluorescent detection, where reagent and microplate interference can cause high background, DELFIA’s TRF-based principle is characterized by lack of sample interference during measurement. This allows for detection of low concentration targets and rare biological events that may be missed using alternative assay methods, and makes DELFIA ideal for complex sample matrices.
Another strong advantage of the platform is its wide dynamic range. Minimizing sample preparation and assay repeats will help to save time and costs, especially when paired with DELFIA’s sensitivity benefits – which lessen sample and antibody requirements. Additionally, the strong stability of lanthanide chelates allow for delayed signal detection and batch processing of experimental workflows, as the signal is not time-sensitive. In fact, plates can be read months later with proper storage.
Because this technology is based on lanthanide chemistry, with a reporter that is not enzyme-based, it eliminates concerns about enzyme quality or degradation, and well as sample contamination. DELFIA assays can also be multiplexed with up to 3 analytes per well, providing excellent analysis flexibility.
Top Benefits of DELFIA:
Platform In Action:
Learn how automation is helping analysts address growing pressures to increase efficiency and output with limited resources.
When your assay must be sensitive, specific, reliable, reproducible, and efficient enough to handle 1,000-1,500 samples in one batch, the BioAgilytix team knows to turn to DELFIA as the platform of choice. Our seasoned scientists will work collaboratively with your own internal scientific team to extend your testing resources with our DELFIA technology and expertise.
Speak with one of BioAgilytix’s DELFIA experts about your bioanalytical project requirements today.
See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.
Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.
Platforms
Services